Tavo Espinoza is the Chief Financial Officer at Ligand Pharmaceuticals Inc., a position he has held since joining the company in 2017. With over two decades of experience in financial management and strategic planning, Espinoza has played a pivotal role in steering Ligand's financial strategies and ensuring the company's growth and sustainability. Prior to Ligand, he held significant roles at companies such as Amylin Pharmaceuticals and DURECT Corporation, where he honed his skills in corporate finance and investor relations. At Ligand Pharmaceuticals, Espinoza is responsible for overseeing all financial aspects of the company, including financial planning and analysis, accounting, and treasury operations. His leadership has been instrumental in driving Ligand's financial performance, evidenced by the company's consistent revenue growth and robust financial health. Under his guidance, Ligand has successfully navigated the complexities of the pharmaceutical industry, making strategic investments and acquisitions that have bolstered its portfolio and market position. Espinoza's achievements extend beyond his role at Ligand. He is recognized in the industry for his strategic foresight and ability to foster strong relationships with investors and stakeholders. His contributions have been acknowledged through various industry awards and recognitions, highlighting his impact on Ligand's success and the broader pharmaceutical sector. Espinoza's dedication to excellence and his strategic approach continue to be vital assets for Ligand Pharmaceuticals as it advances its mission to improve human health through innovative therapies.